Viewpoint: Pathway-sensitive eligibility for biologic therapy in COPD: The role of primary care, phenotyping, and eosinophil-guided management.

Abstract excerpt

There is currently increasing interest in the heterogeneity of airway inflammation in COPD, to implement precision medicine that individualizes treatment based on clinical and biological characteristics. The recognition of T2 inflammation is important, since it describes a distinct subgroup of COPD patients with different biological mechanisms, different clinical presentation, accelerated lung function decline...

Topics

• Humans
• Pulmonary Disease, Chronic Obstructive
• Eosinophils
• Primary Health Care
• Phenotype
• Biological Products